Global Pneumonia Vaccines Market to reach a market size of $9.6 billion by 2025- KBV Research
According to a new report Global Pneumonia Vaccines Market, published by KBV research, The Global Pneumonia Vaccines Market size is expected to reach $9.6 billion by 2025, rising at a market growth of 5.1% CAGR during the forecast period.
The North America market dominated the Global Pneumococcal Conjugate Vaccine (PCV) Market by Region in 2018, growing at a CAGR of 2.8 % during the forecast period. The Europe market is expected to witness a CAGR of 3.6% during (2019-2025). Additionally, The Asia Pacific market is expected to witness a CAGR of 5.3% during (2019-2025).
The Prevnar 13 market dominated the Global Pneumonia Vaccines Market by Product Type in 2018, growing at a CAGR of 4.1 % during the forecast period. The Synflorix market is expected to witness a CAGR of 7.5% during (2019-2025). Additionally, The Pneumovax23 market is expected to witness highest CAGR of 8.5% during (2019-2025).
The Distribution Partner Companies market dominated the Global Pneumonia Vaccines Market by Distribution Channel in 2018, growing at a CAGR of 4.3 % during the forecast period. The Non-Governmental Organizations (NGO) market is expected to witness a CAGR of 6% during (2019-2025).
Full Report: https://www.kbvresearch.com/pneumonia-vaccines-market/
The market research report has exhaustive quantitative insights providing a clear picture of the market potential in various segments across the globe with country wise analysis in each discussed region. The key impacting factors of the market have been discussed in the report with the elaborated company profiles of Glaxosmithkline Plc. (GSK), LG Corporation, Panacea Biotec Limited, Pfizer, Inc., Pnuvax Incorporated, Poonawalla Investments & Industries Pvt. Ltd., Shenzhen Kangtai Biological Products Co., Ltd., SK Holdings Co., Ltd., Walvax Biotechnology Co., Ltd. and MERCK & CO., Inc.
Global Pneumonia Vaccines Market Segmentation
By Vaccine Type
Pneumococcal conjugate vaccine (PCV)
Pneumococcal polysaccharide vaccine (PPSV/PPV)
By Product Type
Prevnar 13
Synflorix
Pneumovax23
By Sector
Public sector
Private sector
By Distribution Channel
Distribution partner companies
Non-governmental Organizations (NGO)
Government Authorities
By Geography
North America
US
Canada
Mexico
Rest of North America
Europe
Germany
UK
France
Russia
Spain
Italy
Rest of Europe
Asia Pacific
China
Japan
India
South Korea
Singapore
Malaysia
Rest of Asia Pacific
LAMEA
Brazil
Argentina
UAE
Saudi Arabia
South Africa
Nigeria
Rest of LAMEA
Companies Profiled
Glaxosmithkline Plc. (GSK)
LG Corporation
Panacea Biotec Limited
Pfizer, Inc.
Pnuvax Incorporated
Poonawalla Investments & Industries Pvt. Ltd.
Shenzhen Kangtai Biological Products Co., Ltd.
SK Holdings Co., Ltd.
Walvax Biotechnology Co., Ltd.
Merck & Co., Inc.
Pneumonia Vaccines Market Related Reports: